
    
      This will be a multi-centre, open label, single treatment, uncontrolled study. A total of 100
      iron-overloaded pediatric patients with transfusion-dependent anemia will be enrolled in the
      study.Eligible patients will receive Ferriprox (deferiprone) oral solution, 100 mg/mL, at a
      total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided in three (3)
      doses, for 24 weeks.
    
  